MaxCyte Appoints Parmeet Ahuja as CFO Effective March 30, 2026
MaxCyte has appointed Parmeet Ahuja as CFO effective March 30, 2026, succeeding Douglas Swirsky after his announced departure in November 2025. Ahuja brings over 20 years of finance leadership at Agilent Technologies, including strategic FP&A and investor relations roles, to support the company’s next growth phase.
1. CFO Appointment and Transition
MaxCyte has named Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. He succeeds Douglas Swirsky, who will transition out after his November 2025 departure announcement.
2. Ahuja’s Finance Leadership Background
Ahuja brings over two decades of experience from a global life sciences company, most recently serving as Vice President of Investor Relations at Agilent Technologies. His roles have spanned operational finance, FP&A, enterprise audit and controls, and global financial operations.
3. Strategic Financial Focus and Growth
The company expects Ahuja to strengthen financial operations and enhance strategic planning through disciplined execution and robust investor relations. His appointment aims to support MaxCyte’s expansion of its electroporation and gene-editing platforms and drive the next phase of growth.